Ranbaxy has recorded an 11% increase in revenues and a strong 42% increase in bottomline. Exports constituted 64% of the total revenues. For 1HFY04, Ranbaxy has reported a 51% increase in topline and 59% increase in bottomline.
(Rs m) | 2QFY03 | 2QFY04 | Change | 1HFY03 | 1HFY04 | Change |
Net Sales | 7,448 | 8,277 | 11.1% | 13,158 | 19,174 | 45.7% |
Other Income | 25 | 931 | 3624.0% | 55 | 987 | 1694.5% |
Operating expenses | 5,827 | 6,642 | 14.0% | 10,584 | 14,112 | 33.3% |
Operating Profit (EBDIT) | 1,621 | 1,635 | 0.9% | 2,574 | 5,062 | 96.7% |
Operating Profit Margin (%) | 21.8% | 19.8% | 19.6% | 26.4% | ||
Interest (net) | 53 | 17 | -67.9% | 181 | 23 | -87.3% |
Depreciation | 203 | 188 | -7.4% | 401 | 367 | -8.5% |
Profit before tax and extraordinary items | 1,390 | 2,361 | 69.9% | 2,047 | 5,659 | 176.5% |
Extra-ordinary Items | 356 | 48 | -86.5% | 920 | 97 | -89.5% |
Tax | 362 | 441 | 21.8% | 634 | 990 | 56.2% |
Profit after Tax | 1,384 | 1,968 | 42.2% | 2,333 | 4,766 | 104.3% |
Net profit margin (%) | 18.6% | 23.8% | 17.7% | 24.9% | ||
No. of Shares (eoy) (m) | 116.0 | 185.0 | 116.0 | 185.0 | ||
Diluted earnings per share* | 29.9 | 42.6 | 25.2 | 51.5 | ||
P/E ratio | 19.1 | 15.8 | ||||
(* annualised) |
Other income has seen a sharp rise on account of the the company receiving its share of revenues from Bayer for the sale of Ciprofloxacin OD. An increase in the R&D expenditure from Rs 365 m to Rs 486 m has resulted in a marginal drop in the operating margins.
Rs m | 2QFY03 | 2QFY04 | Change |
Sales | 9,585 | 11,349 | 18.4% |
Operating Profit | 2,061 | 3,130 | 51.9% |
Operating Margins (%) | 21.5% | 27.6% | |
Net Profit | 1,709 | 2,062 | 20.7% |
Net Margins (%) | 17.8% | 18.2% |
Ranbaxy had restructured its debt portfolio by borrowing US$ 10 m through the ECB route and repaying its high cost debt. The company has thus been able to bring down its interest cost by 38%. This coupled with a drop in the depreciation expenses has helped Ranbaxy record a sharp improvement in its net margin. On a consolidated basis, Ranbaxy has registered an 18% growth in the topline and a 21% increase in the bottomline during the quarter.
The stock is currently trading at Rs 812 implying a P/E of 16x its annualised 1HFY04 earnings. Considering Ranbaxy’s strong growth potential in the generics segment, which has been given a boost with the US government reducing the time period for drug approval and the inclusion of generics in the US government sponsored 'Medicare' policy, combined with its focus on developing a strong NCE and ANDA pipeline, the company has good long-term prospects. However, the risk profile of the stock is also on the higher end given the inherent risks involved in NCE research and complex regulatory procedures on the ANDA front.
Sorry! There are no related views on news for this company/sector.
Ajit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More
Equitymaster requests your view! Post a comment on "Ranbaxy: Right growth prescription`". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!